Literature DB >> 28331046

Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.

Emanuele Pontali1, Lia D'Ambrosio2,3, Rosella Centis2, Giovanni Sotgiu4, Giovanni Battista Migliori5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28331046     DOI： 10.1183/13993003.00146-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

1.  Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Authors:  Alberto L Garcia-Basteiro; Ernie Wong; Pouline M Van Oort; Catia Cilloniz; Giovanni Battista Migliori; Aran Singanayagam
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: A report of 12 cases.

Authors:  Innocent Murhula Kashongwe; Fina Mawete; Nicole Anshambi; Nadine Maingowa; Murielle Aloni; Luc Lukaso L'osenga; Michel Kaswa; Zacharie Munogolo Kashongwe
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-09-22

4.  Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.

Authors:  Sundari Mase; Terence Chorba; Samuel Parks; Ann Belanger; Felicia Dworkin; Barbara Seaworth; Jon Warkentin; Pennan Barry; Neha Shah
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

5.  Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Authors:  Andrey Maryandyshev; Emanuele Pontali; Simon Tiberi; Onno Akkerman; Shashank Ganatra; Tsetan Dorji Sadutshang; Jan-Willem Alffenaar; Rohit Amale; Jai Mullerpattan; Sonam Topgyal; Zarir Farokh Udwadia; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Emerg Infect Dis       Date:  2017-10-17       Impact factor: 6.883

Review 6.  What lies beneath the airway mucosal barrier? Throwing the spotlight on antigen-presenting cell function in the lower respiratory tract.

Authors:  Saparna Pai; Visai Muruganandah; Andreas Kupz
Journal:  Clin Transl Immunology       Date:  2020-07-23

Review 7.  Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy.

Authors:  Anna Cristina Calçada Carvalho; Claudete Aparecida Araújo Cardoso; Terezinha Miceli Martire; Giovanni Battista Migliori; Clemax Couto Sant'Anna
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

Review 8.  New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Authors:  Denise Rossato Silva; Margareth Dalcolmo; Simon Tiberi; Marcos Abdo Arbex; Marcela Munoz-Torrico; Raquel Duarte; Lia D'Ambrosio; Dina Visca; Adrian Rendon; Mina Gaga; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

9.  TB management in the European Union/European Economic Area: a multi-centre survey.

Authors:  G Sotgiu; S Rosales-Klintz; R Centis; L D'Ambrosio; R Verduin; A M Correia; A Cirule; R Duarte; B Gadzheva; G Gualano; H Kunst; F Palmieri; V Riekstina; D Stefanova; S Tiberi; M J van der Werf; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2021-02-01       Impact factor: 2.373
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.